Comparison of IgG Against COVID-19 Between Postmenopausal and Nonmenopausal Women Vaccinated With Sinopharm Vaccine.

OBJECTIVE: Since December 2019, the coronavirus disease has spread among the people of the world. Past studies have shown that viral diseases are more common and the immune response is stronger among menopausal women than nonmenopausal women. Therefore, in this study, we aimed to compare the amount of immunoglobulin (Ig)G against COVID-19 between postmenopausal and nonmenopausal women vaccinated with Sinopharm vaccine. METHODS: In this case-control study, 90 females vaccinated with the Sinopharm vaccine were randomly selected from February to April 2022: 45 menopausal participants as the case group and 45 nonmenopausal controls. Demographic characteristics were obtained and blood samples were taken from all subjects. A complete blood count was carried out and the levels of IgG against COVID-19 were measured by using the enzyme-linked immunosorbent assay method. RESULTS: The mean age was 33.3 ±â€…7.3 years and 60.2 ±â€…7.02 years for control and menopausal women, respectively. A significant difference was found between the 2 groups for the levels of IgG antibodies against COVID-19 (P = .002, 17.2 ±â€…9.83 relative unit for case group and 10.2 ±â€…9.80 relative unit for control subjects). After adjusting, IgG against COVID-19 was significantly correlated to the menopausal state (odds ratio [confidence interval] = 1. 08 [1.03-1. 15]; P = .003). CONCLUSION: The results of this study showed that menopausal women had higher levels of IgG against COVID-19 in comparison with nonmenopausal females. However, more complementary studies are needed in this regard.